Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/136162
Título: | Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trial | Autores/as: | Sánchez-Marteles, Marta Garcés-Horna, Vanesa Morales-Rull, José Luís Casado, Jesús Carrera-Izquierdo, Margarita Conde Martel, Alicia Dávila-Ramos, Melitón Francisco Llácer, Pau Salamanca-Bautista, Prado Ruiz, Raúl Aramburu-Bodas, Oscar Formiga, Francesc Manzano, Luís Trullàs, Joan Carles |
Clasificación UNESCO: | 32 Ciencias médicas 3205 Medicina interna 320501 Cardiología |
Palabras clave: | Acute heart failure Diuretics Hydrochlorothiazide Left ventricular ejection fraction Thiazides |
Fecha de publicación: | 2024 | Publicación seriada: | JACC: Heart Failure | Resumen: | Background: The addition of hydrochlorothiazide (HCTZ) to furosemide in the CLOROTIC (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure) trial improved the diuretic response in patients with acute heart failure (AHF). Objectives: This work aimed to evaluate if these results differ across the spectrum of left ventricular ejection fraction (LVEF). Methods: This post hoc analysis of the randomized, double-blind, placebo-controlled CLOROTIC trial enrolled 230 patients with AHF to receive either HCTZ or a placebo in addition to an intravenous furosemide regimen. The influence of LVEF on primary and secondary outcomes was evaluated. Results: The median LVEF was 55%: 166 (72%) patients had LVEF >40%, and 64 (28%) had LVEF ≤40%. Patients with a lower LVEF were younger, more likely to be male, had a higher prevalence of ischemic heart disease, and had higher natriuretic peptide levels. The addition of HCTZ to furosemide was associated with the greatest weight loss at 72 of 96 hours, better metrics of diuretic response, and greater 24-hour diuresis compared with placebo, with no significant differences according to the LVEF category (using 2 LVEF cutoff points: 40% and 50%) or LVEF as a continuous variable (all P values were insignificant). There were no significant differences observed with the addition of HCTZ in terms of mortality, rehospitalizations, or safety endpoints (impaired renal function, hyponatremia, and hypokalemia) among the 2 LVEF groups (all P values were insignificant). Conclusions: Adding HCTZ to intravenous furosemide seems to be effective strategy for improving diuretic response in AHF without treatment effect modification according to baseline LVEF. (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure [CLOROTIC], NCT01647932; Randomized, double blinded, multicenter study, to asses Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics vs Loop diuretics with placebo in Patients With Decompensated, EudraCT Number 2013-001852-36) | URI: | http://hdl.handle.net/10553/136162 | ISSN: | 2213-1779 | DOI: | 10.1016/j.jchf.2024.05.006 | Fuente: | JACC: Heart Failure [ISSN 2213-1779], v. 12 (10), pp. 1719-1730 |
Colección: | Artículos |
Citas SCOPUSTM
2
actualizado el 16-feb-2025
Citas de WEB OF SCIENCETM
Citations
1
actualizado el 16-feb-2025
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.